Soluble and Cell–Cell-Mediated Drivers of Proteasome Inhibitor Resistance in Multiple Myeloma

Inhibition of thioredoxin activates mitophagy and overcomes adaptive bortezomib resistance in multiple myeloma

(2018) Zhihong Zheng et al.   Journal of Hematology & Oncology

An overview of the role of carfilzomib in the treatment of multiple myeloma

(2017) Dimitrios C. Ziogas et al.   EXPERT OPINION ON PHARMACOTHERAPY

Outcome and survival of myeloma patients diagnosed 2008–2015. Real-world data on 4904 patients from the Swedish Myeloma Registry

(2017) Cecilie Hveding Blimark et al.   HAEMATOLOGICA

The MIP-1α autocrine loop contributes to decreased sensitivity to anticancer drugs

(2017) Masanobu Tsubaki et al.   JOURNAL OF CELLULAR PHYSIOLOGY

ClC5 Decreases the Sensitivity of Multiple Myeloma Cells to Bortezomib via Promoting Pro-Survival Autophagy

(2017) Huimin Zhang et al.   ONCOLOGY RESEARCH

Selinexor Overcomes Hypoxia-Induced Drug Resistance in Multiple Myeloma

(2017) Barbara Muz et al.   Translational Oncology

Effects of DTX3L on the cell proliferation, adhesion, and drug resistance of multiple myeloma cells

(2017) Yaodong Shen et al.   TUMOR BIOLOGY

MK2206 enhances the cytocidal effects of bufalin in multiple myeloma by inhibiting the AKT/mTOR pathway

(2017) Ru-Fang Xiang et al.   Cell Death & Disease

BAFF is involved in macrophage-induced bortezomib resistance in myeloma

(2017) Jing Chen et al.   Cell Death & Disease

Jagged1-induced Notch activation contributes to the acquisition of bortezomib resistance in myeloma cells

(2017) Yukari Muguruma et al.   Blood Cancer Journal

Glutaminase inhibitor CB-839 synergizes with carfilzomib in resistant multiple myeloma cells

(2017) Ravyn M. Thompson et al.   Oncotarget

Emerging drugs and combinations to treat multiple myeloma

(2017) Alessandra Larocca et al.   Oncotarget

Outcome and survival of myeloma patients diagnosed 2008–2015. Real-world data on 4904 patients from the Swedish Myeloma Registry

(2017) Cecilie Hveding Blimark et al.   HAEMATOLOGICA

Proteasome stress sensitizes malignant pleural mesothelioma cells to bortezomib-induced apoptosis

(2017) Fulvia Cerruti et al.   Scientific Reports

Multiple myeloma in the marrow: pathogenesis and treatments

(2016) Heather Fairfield et al.   Annals of the New York Academy of Sciences

TrxR1 inhibition overcomes both hypoxia-induced and acquired bortezomib resistance in multiple myeloma through NF-кβ inhibition

(2016) Prahlad V. Raninga et al.   CELL CYCLE

The stress-inducible transcription factor ATF4 accumulates at specific rRNA-processing nucleolar regions after proteasome inhibition

(2016) Valentina Galimberti et al.   EUROPEAN JOURNAL OF CELL BIOLOGY

Polyphyllin I induces cell cycle arrest and apoptosis in human myeloma cells via modulatingβ-catenin signaling pathway

(2016) Yun Liang et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

PAX5 interacts with RIP2 to promote NF-κB activation and drug-resistance in B-lymphoproliferative disorders

(2016) Dong Wang et al.   JOURNAL OF CELL SCIENCE

SGK Kinase Activity in Multiple Myeloma Cells Protects against ER Stress Apoptosis via a SEK-Dependent Mechanism

(2016) B. Hoang et al.   MOLECULAR CANCER RESEARCH

Aspirin enhances the cytotoxic activity of bortezomib against myeloma cells via suppression of Bcl-2, survivin and phosphorylation of AKT

(2016) Jiang-Hua Ding et al.   Oncology Letters

Cyclin D1 unbalances the redox status controlling cell adhesion, migration, and drug resistance in myeloma cells

(2016) Sophie Bustany et al.   Oncotarget

Anticancer drug bortezomib increases interleukin-8 expression in human monocytes

(2015) Shannon Sanacora et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Halting pro-survival autophagy by TGFβ inhibition in bone marrow fibroblasts overcomes bortezomib resistance in multiple myeloma patients

(2015) M A Frassanito et al.   LEUKEMIA

Study on the Association Between miRNA-202 Expression and Drug Sensitivity in Multiple Myeloma Cells

(2015) Xianjuan Shen et al.   PATHOLOGY & ONCOLOGY RESEARCH

The small heat shock protein B8 (HSPB8) confers resistance to bortezomib by promoting autophagic removal of misfolded proteins in multiple myeloma cells

(2015) Mohamed-Amine Hamouda et al.   Oncotarget

Targeting survival and cell trafficking in multiple myeloma and Waldenstrom macroglobulinemia using pan-class I PI3K inhibitor, buparlisib

(2014) Ilyas Sahin et al.   AMERICAN JOURNAL OF HEMATOLOGY

Bone marrow stromal cell-derived exosomes as communicators in drug resistance in multiple myeloma cells

(2014) J. Wang et al.   BLOOD

PI3KCA plays a major role in multiple myeloma and its inhibition with BYL719 decreases proliferation, synergizes with other therapies and overcomes stroma-induced resistance

(2014) Feda Azab et al.   BRITISH JOURNAL OF HAEMATOLOGY

Engineered nanomedicine for myeloma and bone microenvironment targeting

(2014) A. Swami et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Hypoxia promotes stem cell-like phenotype in multiple myeloma cells

(2014) B Muz et al.   Blood Cancer Journal

BM mesenchymal stromal cell–derived exosomes facilitate multiple myeloma progression

(2013) Aldo M. Roccaro et al.   JOURNAL OF CLINICAL INVESTIGATION

Protein Kinase CK2 Inhibition Down Modulates the NF-κB and STAT3 Survival Pathways, Enhances the Cellular Proteotoxic Stress and Synergistically Boosts the Cytotoxic Effect of Bortezomib on Multiple Myeloma and Mantle Cell Lymphoma Cells

(2013) Sabrina Manni et al.   PLoS One

Differentiation induction enhances bortezomib efficacy and overcomes drug resistance in multiple myeloma

(2012) Jing-li Gu et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Dll1/Notch activation contributes to bortezomib resistance by upregulating CYP1A1 in multiple myeloma

(2012) Dehui Xu et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma

(2012) D. J. Kuhn et al.   BLOOD

BLyS expression and JNK activation may form a feedback loop to promote survival and proliferation of multiple myeloma cells

(2012) G. Xu et al.   CYTOKINE

Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide

(2012) YAWARA KAWANO et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

The dual PI3K and mTOR inhibitor NVP-BEZ235 exhibits anti-proliferative activity and overcomes bortezomib resistance in mantle cell lymphoma cells

(2012) Areumnuri Kim et al.   LEUKEMIA RESEARCH

Anti-tumor activity against multiple myeloma by combination of KW-2478, an Hsp90 inhibitor, with bortezomib

(2012) T Ishii et al.   Blood Cancer Journal

Knockdown of c-Met enhances sensitivity to bortezomib in human multiple myeloma U266 cells via inhibiting Akt/mTOR activity

(2011) WENZHONG QUE et al.   APMIS

Multiple Myeloma Mesenchymal Stem Cells: Characterization, Origin, and Tumor-Promoting Effects

(2011) M. R. Reagan et al.   CLINICAL CANCER RESEARCH

Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells

(2011) N E Franke et al.   LEUKEMIA

Bortezomib resistance in a myeloma cell line is associated to PSMβ5 overexpression and polyploidy

(2011) Patricia Balsas et al.   LEUKEMIA RESEARCH

Monitoring a Nuclear Factor-κB Signature of Drug Resistance in Multiple Myeloma

(2011) Yun Xiang et al.   MOLECULAR & CELLULAR PROTEOMICS

Molecular Mechanisms of Bortezomib Resistant Adenocarcinoma Cells

(2011) Erika Suzuki et al.   PLoS One

Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress

(2010) M Ri et al.   LEUKEMIA

Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-κB activity in myeloma cells

(2010) Stephanie Markovina et al.   Molecular Cancer

NF-κB/STAT3/PI3K signaling crosstalk in iMycEμ B lymphoma

(2010) Seong-Su Han et al.   Molecular Cancer

Critical role of PI3K signaling for NF- B-dependent survival in a subset of activated B-cell-like diffuse large B-cell lymphoma cells

(2010) B. Kloo et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Molecular basis of bortezomib resistance: proteasome subunit  5 (PSMB5) gene mutation and overexpression of PSMB5 protein

(2008) R. Oerlemans et al.   BLOOD

Bortezomib overcomes cell adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma

(2008) K Hatano et al.   ONCOGENE